Key Metrics of Amarin Corporation plc
Revenue$307M▼ 16.9% YoYFY 2023
Operating income−$67.6M▲ 36.2% YoY
Net profit−$55.0M▲ 48.0% YoY
Shareholders' equity$552M
Market cap$249MAMRN · $12.05
Competitors10identified
About Amarin Corporation plc
Sectors
Company details
- Listed
- Nasdaq: AMRN
Operational Areas of Amarin Corporation plc
Pharmaceuticals & Healthcare›Biotechnology & Vaccines
Company summary
Legal nameAmarin Corporation plc
TickerAMRN
ExchangeNasdaq
CountryIreland
SEC CIK0000897448
Listed since—
IndustryBiotechnology: Pharmaceutical Preparations
SectorPharmaceuticals & Healthcare · Biotechnology & Vaccines
Website—
US market & SEC filings
AMRN · Nasdaq · SEC CIK 0000897448
Last price · 04 Nov 2026
$12.05
−0.66%
Market cap$249M
P/E—On FY 2023 diluted EPS
Volume91,648
SectorHealth CareBiotechnology: Pharmaceutical Preparations
Country · IPOIreland
AMRN share price
Premium
Annual results (SEC EDGAR)
Revenue, operating income, net income, EPS, cash flow, assets, liabilities, equity and debt for every year filed with the SEC are part of the premium plan.
Sign in to continue See plans & pricingVendor checks & payment capacity
Sign in with access to company financials to review vendor evidence.
Registered office and contact
Registered office—
GSTIN—
Email—
Website—
Members / shareholders—
Directors and key people
Directors are read from the MGT-7 annual return and AOC-4 signatories.
Competitors of Amarin Corporation plc
Competitors10identified
Countries2most in United States
Top competitors by location
| Company | Description | Domain | Founded | Location |
|---|---|---|---|---|
| Part of Vertex Pharmaceuticals. | vrtx.com | 1991 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | gsk.com | 2022 | United Kingdom | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | modernatx.com | 2018 | United States | |
 Becton Dickinson |
Biotechnology & Vaccines · Pharmaceuticals & Healthcare | bd.com | — | United States |
| Part of Illumina. | illumina.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | guardanthealth.com | 2018 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | revvity.com | — | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | exelixis.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | neurocrine.com | 1996 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | biomarin.com | 1999 | United States |
Charges (secured borrowings)
0 registered charges. Lenders, amounts and dates are part of the premium plan.
Statutory auditors
Auditors are read from the AOC-4 auditor's report section.
Business activities and related parties
Principal business activities and related-party transactions are read from MGT-7 and AOC-4 filings.
Filings
No filings on record yet.